Healthy subjects
Conditions
Interventions
five:esomeprazole
Sponsors
Clinical Pharmacology Institution, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. healthy volunteers, aged 18 to 40 years, including the boundary value; the same age difference of not more than 10 years of age; 2. weight greater than 50 kg, the subjects of body mass index (BMI) between 19 ~ 24 kg/m2, including the boundary values of the same batch weight difference should not be different; 3. physical examination showed no abnormalities. No history of drug allergy; 4. no history of drug allergy; 5. no smoke, wine hobby; 6. subjects volunteered to participate in the test and to test in accordance with the provisions of the test program; 7. signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. 4 weeks before the trial had a clinically significant disease or had surgery; 2. any laboratory test results are of clinical significance; 3. a drug that is known to have an effect on an organ within 3 months or is currently in use; 4. has a history of drug allergy and is highly sensitive to environmental substances; 5. susceptible to hypokalemia; 6. congestive heart failure, gastric ulcer, glucose -6- phosphate dehydrogenase (G6PD) deficiency, severe liver damage, severe renal impairment; 7. any other history of serious disease or a history of cardiovascular disease, endocrine system, nervous system disease, lung, hematology, immunology, psychiatric disorders, and metabolic disorders; 8. near cold; 9. with active bleeding, diabetes, glaucoma and other diseases; 10. HIV positive test; 11. Hepatitis B surface antigen positive or HCV positive; l2. ongoing treatment with any medical significance; 13. to participate in the trial before the same period with drug users; 14. drug abusers; 15. 3 months prior to the trial and taking soft drugs (e.g. marijuana) during the trial or taking hard drugs such as cocaine, benzene, and so on before and during the trial; 16. participated in other drug trials within 3 months; 17. 3 months before the trial to participate in blood donors; 18. with coagulopathy or thromboembolic disease. 19. stomach cold persons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| drug concerntration; | — |
Countries
China
Contacts
Public ContactZhirong Tan
Clinical Pharmacology Institution, Central South University
Outcome results
None listed